Lower dose of betrixaban reduces bleeding in midstage study

03/16/2010 | American City Business Journals

Betrixaban, a Factor Xa inhibitor, appeared to reduce bleeding incidences more than warfarin when given in a 40-milligram dose to patients who had a stroke or nonvalvular atrial fibrillation. The midstage study recorded similar bleeding incidences between warfarin and 60-milligram, as well as 80-milligram, formulations of betrixaban, which is being developed by Merck & Co. and Portola Pharmaceuticals.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC